GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.342
+0.002 (+0.59%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.340
Open0.357
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.340 - 0.365
52 Week Range0.210 - 1.560
Volume739,956
Avg. Volume1,562,304
Market Cap74.547M
Beta (3Y Monthly)-2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.172
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GB Sciences Harvests the First Hemp Crop in Colorado
    PR Newswire4 days ago

    GB Sciences Harvests the First Hemp Crop in Colorado

    Harvesting the first crop, in association with the Colorado Hemp Project, GB Sciences explores hemp as a highly reliable source of hard to find cannabinoids and terpenes for cannabis-based medical formulations as well as a fresh source of revenue from the sale of hemp oil and related products. LAS VEGAS, Oct. 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the harvesting of its first hemp crop in association with the Colorado Hemp Project. Following closely on the overall philosophy and strategy of the Company, hemp is planned to provide both a reliable source of hard to find cannabinoids and terpenes necessary to manufacture cannabis-based medical formulations and also provide a fresh revenue source through the sale of bulk hemp oil and other hemp related products.

  • GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles
    PR Newswire10 days ago

    GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles

    Mr. Poss will speak on GB Sciences' collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids. LAS VEGAS , Oct. 10, 2018 ...

  • GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018
    PR Newswire11 days ago

    GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018

    LAS VEGAS, Oct. 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th. According to the conference organizers, "CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world's top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis.

  • GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds
    PR Newswire17 days ago

    GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds

    GB Sciences explores the therapeutic potential of the chemical diversity within different varieties of the cannabis plant to make better medicine for patients worldwide. LAS VEGAS, Oct. 3, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece.  Titled: The Cannabis Metabolomics ("Canna-bolomics") Project, the program will analyze each of GB Sciences' cultivars to determine whether additional molecules in these cultivars, and hundreds of other natural cannabis and hemp cultivars, show significant promise to treat diseases. "GB Sciences is widening the lens with which we observe and characterize plant-based, cannabis-derived chemical mixtures for human therapies starting from GB Sciences' stock genotypes.

  • PR Newswire18 days ago

    GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization

    LAS VEGAS, Oct. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)'s decision to reschedule GW Pharmaceuticals' Epidiolex, from Schedule I to Schedule V of the Controlled Substances Act (CSA).  In June of 2018, Epidiolex was the first ever plant-based, cannabis drug to be approved by the Food and Drug Administration (FDA). There is now both a regulatory precedent for market approval on a plant-based cannabinoid-containing drug and a path to its commercialization.

  • Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
    PR Newswire24 days ago

    Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies

    GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease SWINDON, U.K. , and LAS VEGAS , Sept. 26, ...

  • GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals
    PR Newswire25 days ago

    GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals

    The new license provides access to the largest growing sectors in the cannabis industry. Multiple new brands for both medical and recreational markets being prepped for retail sales. LAS VEGAS, Sept. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has been granted a recreational production license for the manufacture of cannabis oils.  Oils are the base ingredient for vape products, tinctures, edibles, and nutraceutical formulations.

  • GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"
    PR Newswirelast month

    GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"

    LAS VEGAS, Sept. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX)  has mobilized cannabis industry thought leaders to discuss both the immense potential for cannabis-based therapies and the challenges of delivering on their medical promise under state regulated programs at their fourth annual "Innovation in Medical Cannabis Therapies" symposium on November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, NV. This event has attracted innovative leaders in cannabis biotech, nanotech, metabolomics, cultivation and extraction tech.  GB Sciences is pleased to announce this will include representatives from US and international research universities, cannabis industry leaders, clinical research organizations, and cannabis tech companies.

  • GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary
    PR Newswirelast month

    GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary

    Dr. Andrea Small-Howard is featured in the "Meeting of the Minds" at the two-day educational conference hosted on the historic Queen Mary. LAS VEGAS, Sept. 18, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research Initiatives. Of great interest to this panel is The Medical Cannabis Research Act of 2018, which was unanimously approved by the House Judiciary Committee with widespread bipartisan support on September 13th.

  • The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
    PR Newswire2 months ago

    The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership

    In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program. BATON ROUGE, La. , Aug. 23, 2018 /PRNewswire/ -- GB Sciences, ...

  • GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop
    PR Newswire2 months ago

    GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop

    The first plants generated through tissue culture have now moved into their environmentally controlled cannabis grow pod. BATON ROUGE, La., Aug. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the LSU Agricultural Center (LSU AgCenter), have now commenced operation in the environmentally controlled grow pod. Representatives from nine Louisiana pharmacies authorized to dispense medical cannabis toured our high-tech 36,000-sq ft GB Sciences facility in Baton Rouge, LA.

  • GlobeNewswire2 months ago

    GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year

    For the three months that ended June 30, 2018, GB Sciences, Inc. (GBLX) reported revenue of $1,315,284 and gross profit of  $734,719.  This compares to revenue and gross profit of $69,100 and $54,099, respectively, for the same period the prior year. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

  • Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
    PR Newswire2 months ago

    Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease

    This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial. LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.

  • GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
    PR Newswire3 months ago

    GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"

    This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research. LAS VEGAS, Aug. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in "Cannabinoids, the Heart of the Matter".

  • GlobeNewswire3 months ago

    GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance

    GB Sciences, Inc (GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance Officer Program and Adherence SCORE App (a leading cannabis industry compliance inspection tool) to strengthen overall compliance in all U.S. markets where GB Sciences is currently operating or planning to initiate operations.  “GB Sciences is continually focused on strengthening our enterprise compliance, especially given our aggressive expansion plans and the constantly changing regulatory landscape” said Dr. Dominick Monaco, VP Operations for GB Sciences.

  • GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
    PR Newswire3 months ago

    GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market

    The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations. LAS VEGAS, July 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD, cannabinoids and terpenes to provide the necessary compounds to support both the Company's medical Intellectual Properties portfolio and open a fresh revenue stream in the rapidly growing retail hemp market. The search for a full spectrum hemp oil product that matched the quality and consistency of their cannabis genetics led GB Sciences to The Colorado Hemp Project.

  • GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
    PR Newswire3 months ago

    GB Sciences One of Ten Companies Named in Important New Canadian Research Publication

    LAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.

  • GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
    PR Newswire4 months ago

    GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain

    The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures. LAS VEGAS , June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. ...

  • PR Newswire5 months ago

    GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Covered By Medical Cannabis Legislation

    LAS VEGAS, May 22, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana. The passage of the Alison Neustrom Act in 2015 opened the door for a relatively small number of qualified patients to legally receive medical marijuana treatment. The passage of two new House Bills increases the patient count to include patients with additional qualifying disease conditions in the State.

  • GB Sciences' Acquisition Of NevadaPURE Is Terminated
    PR Newswire5 months ago

    GB Sciences' Acquisition Of NevadaPURE Is Terminated

    LAS VEGAS, May 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms of the non-binding letter of intent signed between the parties and after the due diligence period (which was mutually extended by one week), GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction. GB Sciences' Chairman of the Board and CEO John Poss said: "A nondisclosure agreement between the parties prevents GB Sciences from making extensive comments on the proposed transaction.

  • ACCESSWIRE5 months ago

    Marijuana Stocks for Investors in the Free Cannabis Investor Magazine

    MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...

  • ACCESSWIRE6 months ago

    GB Sciences is Exploring a Cannabis Therapy for Parkinson's, Analysts Review

    The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.

  • ACCESSWIRE6 months ago

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...